Myelodysplastic Syndromes
-
News
MYELODYSPLASTIC SYNDROMES | Advantages of Iron Chelation Revealed in Analysis of Low-Risk MDS
A recent groundbreaking study sheds new light on the effectiveness of iron chelation therapy (ICT) for patients suffering from low-risk myelodysplastic syndromes (LR-MDS). By delving into the impact of ICT…
Read More » -
News
CLINICAL NEWS | FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS
The approval was based on interim results from the pivotal phase 3 COMMANDS trial (ClinicalTrials.gov Identifier: NCT03682536) that evaluated the efficacy and safety of luspatercept in 356 patients with anemia due to international…
Read More »